Screening biomarkers such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and advanced glycation end-products (AGEs) could aid in assessing cardiovascular risk in women with PCOS, though further research and long-term studies are needed to establish clinical guidelines and reference values. The gene discussed is CCL2; the disease is polycystic ovary syndrome.